Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery Nov 20, 2024 07:00AM
Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI) Shareholders Approve the Proposed Merger Nov 13, 2024 09:09AM
Recursion and Exscientia Shareholders Approve the Proposed Combination Nov 13, 2024 09:08AM
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates Nov 7, 2024 08:00AM
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th Oct 30, 2024 08:22AM
View Older Stories

Sep 30, 2024 08:00AM Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
Aug 14, 2024 09:45AM How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
Aug 13, 2024 09:00AM The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and &q
Aug 8, 2024 08:00AM Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
Aug 8, 2024 07:30AM Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
Jun 24, 2024 01:02PM EXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
Jun 21, 2024 09:00AM The Galien Foundation Announces 2024 International Prix Galien and Prix Galien Italy Award Winners
Jun 20, 2024 10:22AM EXSCIENTIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
Jun 12, 2024 06:06PM ROSEN, A LEADING LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
Jun 8, 2024 10:36AM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
Jun 3, 2024 05:05PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
May 20, 2024 05:46PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
May 14, 2024 06:46PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
May 11, 2024 09:25AM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
May 8, 2024 08:23PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
May 3, 2024 04:25PM ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Exscientia plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
Apr 24, 2024 08:00AM The Galien Foundation Announces 2024 Prix Galien International Awards Nominees
Jan 4, 2024 08:00AM Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
Jan 2, 2024 07:00AM Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
Dec 21, 2023 07:01AM Exscientia plc (EXAI) Announces Expansion of its Current Collaboration with Sanofi (SNY)
Dec 21, 2023 07:00AM Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
Dec 5, 2023 07:11AM Exscientia (EXAI) Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
Dec 5, 2023 07:00AM Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
Nov 21, 2023 07:00AM Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
Nov 9, 2023 07:00AM Exscientia Business Update for Third Quarter 2023
Nov 2, 2023 07:00AM Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
Oct 17, 2023 07:00AM Parker Moss to Join Exscientia as EVP, Corporate Development
Oct 16, 2023 07:00AM Exscientia plc (EXAI) to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO
Oct 16, 2023 07:00AM Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
Oct 3, 2023 08:09AM Exscientia (EXAI) Details Pipeline Prioritisation Strategy
Oct 3, 2023 08:00AM Exscientia Details Pipeline Prioritisation Strategy
Sep 20, 2023 07:24AM Exscientia (EXAI) Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
Sep 20, 2023 01:00AM Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
Aug 31, 2023 07:00AM Exscientia to Present at Upcoming Investor Conferences in September
Aug 10, 2023 07:00AM Exscientia Business Update for Second Quarter and First Half of 2023
Aug 3, 2023 07:00AM Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023
Jul 18, 2023 07:02AM Exscientia (EXAI) Initiates Prospective Observational Study in Ovarian Cancer
Jul 18, 2023 07:00AM Exscientia Initiates Prospective Observational Study in Ovarian Cancer
Jul 10, 2023 07:00AM First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
Jun 29, 2023 08:05AM Exscientia plc (EXAI) Expands Technology Leadership Team
Jun 29, 2023 08:05AM Exscientia Announces Expansion of its Technology Leadership Team
Jun 6, 2023 07:00AM Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
May 24, 2023 07:00AM Exscientia Business Update for First Quarter 2023
May 22, 2023 07:00AM Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
May 17, 2023 07:01PM Professor Andrew L. Hopkins elected Fellow of the Academy of Medical Sciences
May 17, 2023 07:00AM Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
May 15, 2023 09:06AM Exscientia (EXAI) Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 15, 2023 09:05AM Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 10, 2023 05:01AM Professor Andrew L. Hopkins elected Fellow of the Royal Society
Apr 19, 2023 09:00AM Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
View Older Stories